Conference Reports for NATAP

62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back

PHARMACOKINETIC MODELING OF ACH-2684, A HEPATOSELECTIVE PHASE I PAN-GENOTYPIC HCV NS3 PROTEASE INHIBITOR: PREDICTIONS AND CORRELATION WITH HUMAN PHARMACOKINETICS       Reported by Jules Levin AASLD Nov 5-9 2011 SF   Kathe Stauber, Elizabeth Olek, Jose Rivera, Christopher Marlor, Lisa Robarge, Minjung Huang, Avinash Phadke, and Milind Deshpande Achillion Pharmaceuticals, Inc. New Haven, CT 06511, USA